Business
Merck buys B-cell disease drug for up to $1.3 billion
Merck has struck a deal worth up to $1.3 billion to buy an experimental drug that targets B-cell-related diseases.
Merck has struck a deal worth up to $1.3 billion to buy an experimental drug that targets B-cell-related diseases.
